Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the Treatment of Metabolic Diseases and Nonalcoholic Steatohepatitis (NASH)

Targeted therapeutics and novel signaling pathways in non-alcohol

Frontiers New insights into the role of dietary triglyceride

MGAT2 inhibitor decreases liver fibrosis and inflammation in

The monoacylglycerol acyltransferase pathway contributes to

Inhibition of Diacylglycerol Acyltransferase 2 Versus

TP-020 (MGAT2-IN-1), MGAT2 Inhibitor

Diseases, Free Full-Text

Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the

The monoacylglycerol acyltransferase pathway contributes to

Inhibition of MGAT2 modulates fat‐induced gut peptide release and

US9701672B2 - Dihydropyridinone MGAT2 inhibitors for use in the